Public Health & Primary Care / Research Article
Cogent Medicine (2018), 5: 1430197
Lefebvre et al., Cogent Medicine (2018), 5: 1430197 https://doi.org/10.1080/2331205X.2018.1430197
This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is
a key component of leprosy treatment, as it is vital to prevent the progression of the infection.
Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with
the ...leprosy infection. Furthermore, the relapse rate is very low, at about 1% over 5–10 years.
There is little M. leprae drug resistance in leprosy and few reports of multi-drug resistance (1, 2, 3,
4, 5, 6, 7, 8). An antibiotic treatment may take months or years to produce clinical improvement,
especially in patients with an initial high bacterial index (BI).
more
Towards Universal Access to Prevention, Diagnosis and Treatment
The document provides detailed guidelines for managing cholera outbreaks, focusing on prevention, diagnosis, treatment, and control strategies. It emphasizes the importance of setting up Cholera Treatment Centers (CTCs), ensuring access to clean water, promoting hygiene, and utilizing oral rehydrati...on solutions (ORS) and antibiotics for treatment. The guide also addresses outbreak surveillance, community education, and resource allocation to effectively mitigate cholera's spread and impact.
more
The immediate objective of the country visit to Senegal was to build upon the public health preparedness already in place and to ensure that systems are available to investigate and report potential EVD cases and to mount an effective response to prevent a larger outbreak. The joint team for strengt...hening preparedness for EVD was composed of representatives of Senegal’s Ministry of Health, WHO, CDC, the United Nations Office for Coordination of Humanitarian Affairs, the European Centres for Disease Prevention and Control, the Erasmus Medical Centre, Netherlands, and John Hopkins University, USA.
more
Interim Guidance 7 March 2020
This document provides technical guidance for government authorities, health workers, and other key stakeholders to guide response to community spread. It will be updated as new information or technical guidance become available. For countries that are already preparin...g or responding, this document can also serve as a checklist to identify any remaining gaps.
more
The roundtable provided a forum that allowed communicators across a number of Federal agencies to share information, strategies, and challenges in developing and providing communication messages and materials to the public in preparation for, and in response to, a radiation... emergency. Throughout the discussion , several “big picture” qestions were brought up that may be addressed in future interagency efforts.
more
This Indicator-Based Pharmacovigilance Assessment Tool (IPAT) was developed as a comprehensive performance metric for pharmacovigilance and medicine safety systems.
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rifampicin-resistant and multi-drug resistant T...B (RR/MDR-TB), only 206 030 (44%) were diagnosed and notified.For the first time, the World Health Organization (WHO) has provided global estimates of the incidence of isoniazid resistance: in 2019, there were 1.4 million incident cases of isoniazid-resistant TB, of which 1.1 million were susceptible to rifampicin. Most of these people were not diagnosed with drug-resistant TB and did not receive appropriate treatment.
more
The EYE strategy is a comprehensive and long-term strategy built on lessons learned that aims at ending yellow fever epidemics by 2026, and consists of three strategic objectives:
protect at-risk populations;
prevent international spread; and
contain outbreaks rapidly.